LianBio Operating Expenses
LianBio (LIANY) reported Operating Expenses of $26.30 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-11-13
- LianBio operating expenses for the quarter ending 2023-09-30 was $26.30M, a 7.14% increase year-over-year.
- LianBio operating expenses for the quarter ending 2023-06-30 was $25.04M, a 41.95% decline year-over-year.
- LianBio operating expenses for the quarter ending 2023-03-31 was $25.97M, a 8.61% decline year-over-year.
- LianBio operating expenses for the quarter ending 2022-12-31 was $29.25M, a 32.71% increase year-over-year.
- LianBio operating expenses for fiscal 2022 was $125.35M, a 35.90% decline from fiscal 2021.
- LianBio operating expenses for fiscal 2021 was $195.57M, a 45.01% increase from fiscal 2020.
- LianBio operating expenses for fiscal 2020 was $134.87M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2023-09-30 | $26.30M 10-Q · filed 2023-11-13 | $51.34M derived: sum of 2 quarters · filed 2023-11-13 | $77.31M 10-Q · filed 2023-11-13 | $106.56M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $25.04M 10-Q · filed 2023-08-14 | $51.01M 10-Q · filed 2023-08-14 | $80.26M derived: sum of 3 quarters · filed 2023-08-14 | $104.81M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $25.97M 10-Q · filed 2023-05-11 | $55.21M derived: sum of 2 quarters · filed 2023-05-11 | $79.76M derived: sum of 3 quarters · filed 2023-11-13 | $122.91M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $29.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $53.79M derived: sum of 2 quarters · filed 2023-11-13 | $96.94M derived: sum of 3 quarters · filed 2023-11-13 | $125.35M 10-K · filed 2023-03-28 |
| 2022-09-30 | $24.55M 10-Q · filed 2023-11-13 | $67.69M derived: sum of 2 quarters · filed 2023-11-13 | $96.11M 10-Q · filed 2023-11-13 | $118.14M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $43.14M 10-Q · filed 2023-08-14 | $71.56M 10-Q · filed 2023-08-14 | $93.59M derived: sum of 3 quarters · filed 2023-08-14 | $107.14M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $28.42M 10-Q · filed 2023-05-11 | $50.45M derived: sum of 2 quarters · filed 2023-05-11 | $64.00M derived: sum of 3 quarters · filed 2023-05-11 | $163.49M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $22.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $35.58M derived: sum of 2 quarters · filed 2023-03-28 | $135.07M derived: sum of 3 quarters · filed 2023-03-28 | $195.57M 10-K · filed 2023-03-28 |
| 2021-09-30 | $13.54M 10-Q · filed 2022-11-10 | $113.03M derived: sum of 2 quarters · filed 2022-11-10 | $173.53M 10-Q · filed 2022-11-10 | $182.74M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $99.49M 10-Q · filed 2022-08-11 | $159.99M 10-Q · filed 2022-08-11 | $169.19M derived: sum of 3 quarters · filed 2022-08-11 | $288.24M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $60.50M 10-Q · filed 2022-05-12 | $69.70M derived: sum of 2 quarters · filed 2022-05-12 | $188.75M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $9.20M derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $128.25M derived: sum of 2 quarters · filed 2022-03-31 | $134.87M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $119.04M 10-Q/A · filed 2022-01-10 | $125.67M 10-Q/A · filed 2022-01-10 |